MGP
TEVA icon

Metis Global Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Metis Global Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
28,999
+4,844
+20% +$161K 0.02% 445
2026
Q1 		$728K Buy
24,155
+1,822
+8% +$58.6K 0.02% 511
2025
Q4 		$697K Buy
22,333
+6,084
+37% +$150K 0.02% 531
2025
Q3 		$328K Buy
16,249
+848
+6% +$14.9K 0.01% 653
2025
Q2 		$258K Buy
15,401
+1,749
+13% +$28.2K 0.01% 672
2025
Q1 		$210K Sell
13,652
-45
-0.3% -$804 0.01% 724
2024
Q4 		$302K Buy
13,697
+860
+7% +$15.6K 0.01% 665
2024
Q3 		$231K Buy
12,837
+359
+3% +$6.28K 0.01% 709
2024
Q2 		$203K Buy
+12,478
New +$192K 0.01% 720

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Metis Global Partners's TEVA Position: Q2 2026 in Review

Metis Global Partners increased its Teva Pharmaceuticals (TEVA) stake by 20% in Q2 2026, buying an estimated $161K and bringing the position to 28,999 shares worth $982K. The position accounts for 0.02% of the portfolio, ranked #445.

Metis Global Partners first reported a position in TEVA in Q2 2024 and has held it in 9 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Metis Global Partners held 28,999 shares of Teva Pharmaceuticals worth $982K as of Q2 2026.
  • Metis Global Partners bought 4,844 Teva Pharmaceuticals shares in Q2 2026, an estimated $161K.
  • Teva Pharmaceuticals made up 0.02% of Metis Global Partners's portfolio in Q2 2026, its #445 holding.
  • Metis Global Partners first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.